In 2015, Pansend Life Sciences of INNOVATE Corp. (NYSE: VATE) became the largest equity investor in MediBeacon. In 2019, MediBeacon entered into a $30 million investment and exclusive commercialization partnership in Greater China with Huadong Medicine Co., Ltd. Huadong is a leading China-based pharmaceutical company listed on the Shenzhen Stock Exchange.
MediBeacon’s fluorescent agent platform for use in physiological function monitoring has important applications in kidney health, gastrointestinal health, and beyond.